Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus with Methotrexate and Cyclosporine for GVHD Prevention in Marrow Transplantation
NCT00002790Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 1996
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Maximum Tolerated Dose of Rapamycin. Planned start Mar 1996; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00002790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002790.